Showing 321 - 340 results of 16,767 for search '(( 50 ms decrease ) OR ( 50 ((((ng decrease) OR (a decrease))) OR (mean decrease)) ))', query time: 0.68s Refine Results
  1. 321
  2. 322
  3. 323
  4. 324

    Inclusion of TPP side chains result in decreased melanoma cell mitochondria membrane potential, oxygen consumption, and increased DHE oxidation. by Kyle C. Kloepping (9928265)

    Published 2020
    “…At the 25 min mark, 1.0 μM 12-TPP was added to treatment A375 cells followed by the sequential addition of 2.5 μM oligomycin at the 60 min mark, 0.3 μM oligomycin at the 90 min mark, and 5.0 μM rotenone/antimycin A at the 120 min mark. …”
  5. 325
  6. 326
  7. 327
  8. 328
  9. 329
  10. 330
  11. 331
  12. 332
  13. 333
  14. 334
  15. 335
  16. 336
  17. 337
  18. 338
  19. 339

    Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>In the recurrence group, mean outpatient visits (± standard deviation) decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
  20. 340

    Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>The number of anti-VEGF treatments, STTA, MA-PC, PPV, and total treatments (mean ± SD) significantly decreased from 2.6 ± 1.6, 0.3 ± 0.8, 0.6 ± 0.8, 0.1 ± 0.3, and 3.7 ± 1.7 preoperatively to 0.8 ± 1.9, 0.0 ± 0.2, 0.3 ± 1.0, 0.0, and 1.2 ± 2.2; at year 2 to 0.7 ± 2.0, 0.1 ± 0.6, 0.0 ± 0.2, 0.0 ± 0.2, and 1.0 ± 2.1; and at year 3 to 0.9 ± 2.2, 0.0, 0.2 ± 1.0, 0.0 ± 0.2, and 1.1 ± 3.1 (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”